Literature DB >> 29758553

A Retrospective Cohort Study on Patients with Hidradenitis Suppurativa.

S Morteza Seyed Jafari1, Evelyne Knüsel1, Simone Cazzaniga1,2, Robert E Hunger1.   

Abstract

BACKGROUND: Hidradenitis suppurativa (HS) is one of the most distressing conditions observed in dermatology and has a substantial negative effect on the quality of life of affected persons.
OBJECTIVES: The aim of this study was to evaluate different treatment strategies in patients with HS.
METHODS: In a retrospective cohort, all patients with HS (July 2015 to March 2017) were reviewed. Collected data consisted of patients' demographics, clinical characteristics, psychosocial situation, and previous and current treatments. In addition, therapy response to the most recent prescribed treatments was assessed.
RESULTS: 102 patients (38 females, 64 males; median age 37.5 years) were included in this study. 68.4% of patients had BMI ≥25, and 76.5% of patients were current smokers. Hurley stages I, II, and III were detected in 13.5, 53.1, and 33.3% of patients, respectively. The most commonly administered treatments were surgery (67.6%), nonantibiotic topical therapies (72.5%), antibiotic topical therapies (55.9%), systemic antibiotics (88.2%), and biologics in 11.8% of the patients. 84.6% of the patients showed a response (27.5 and 47.1% partial and complete response, respectively) to the treatments.
CONCLUSION: HS as a chronic, recurrent inflammatory skin disease is associated with smoking and obesity. Application of systemic antibiotics is the most frequent treatment strategy for this disease. However, surgical intervention seems to be the most effective treatment strategy.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Hidradenitis suppurativa; Quality of life; Treatment

Mesh:

Substances:

Year:  2018        PMID: 29758553     DOI: 10.1159/000488344

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  6 in total

Review 1.  Non-contrast-enhanced 3-Tesla Magnetic Resonance Imaging Using Surface-coil and Sonography for Assessment of Hidradenitis Suppurativa Lesions.

Authors:  Fatemeh Jabbary Lak; Mona Mazinani; Johannes T Heverhagen; Robert E Hunger; Keivan Daneshvar; S Morteza Seyed Jafari
Journal:  Acta Derm Venereol       Date:  2020-11-12       Impact factor: 3.875

Review 2.  Hidradenitis suppurativa; classification, remedies, etiology, and comorbidities; a narrative review.

Authors:  Sadaf Mohammadi; Abbas Gholami; Lina Hejrati; Masoomeh Rohani; Raheleh Rafiei-Sefiddashti; Alireza Hejrati
Journal:  J Family Med Prim Care       Date:  2021-11-29

3.  Outcome Comparison of Different Reconstructive Approaches for Axillary Defects Secondary to Radical Excision of Hidradenitis Suppurativa.

Authors:  Vlad Tereshenko; Riccardo Schweizer; Matthias Waldner; Bong-Sung Kim; Pietro Giovanoli; Holger Jan Klein
Journal:  Dermatology       Date:  2022-01-27       Impact factor: 5.197

4.  Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data.

Authors:  Aikaterini Kyriakou; Anastasia Trigoni; Nikiforos Galanis; Dimitrios Sotiriadis; Aikaterini Patsatsi
Journal:  Dermatol Reports       Date:  2018-10-01

Review 5.  Hidradenitis Suppurativa: Current Understanding of Pathogenic Mechanisms and Suggestion for Treatment Algorithm.

Authors:  S Morteza Seyed Jafari; Robert E Hunger; Christoph Schlapbach
Journal:  Front Med (Lausanne)       Date:  2020-03-04

6.  Creation of a severity index for hidradenitis suppurativa that includes a validated quality-of-life measure: the HIDRAscore.

Authors:  A V Marzano; A Chiricozzi; G Giovanardi; G Argenziano; V Bettoli; L Bianchi; P Dapavo; V Dini; G Fabbrocini; G Micali; A M Offidani; C Potenza; F Prignano; G Gualberti; V Saragaglia; F Rongioletti
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-05-12       Impact factor: 6.166

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.